Which scan spots hidden tumors best? new study aims to find out

NCT ID NCT05255159

Ongoing Diagnosis Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get all three scans, and results will be compared lesion by lesion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG (radioactive tracers used in PET/CT scans)
What this could lead to: If successful, this could help doctors choose the best scan to detect all tumor spots, leading to more accurate staging and better treatment decisions for people with neuroendocrine tumors.
What could go wrong: This is a small, early-phase study (50 people) at one center. It compares scans but does not test a new treatment, so any impact on patient outcomes is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 lung neuroendocrine neoplasm medullary thyroid gland carcinoma medulloblastoma meningioma neuroendocrine neoplasm pancreatic neuroendocrine tumor paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

University of Alberta Hospital

Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.